|
Acute alcoholic liver disease
|
0.200 |
Therapeutic
|
disease |
RGD |
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
|
27939985 |
2017 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Liver Cirrhosis
|
0.220 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Metabolic Syndrome X
|
0.220 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Fibrosis, Liver
|
0.210 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Colitis
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.
|
27580383 |
2016 |
|
Insulin Resistance
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Necrosis
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
Fibroblast growth factor 15 deficiency impairs liver regeneration in mice.
|
24699334 |
2014 |
|
Insulin Sensitivity
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Hepatic Insufficiency
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
|
25822088 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, our results offer preclinical proof of concept for H3B-6527 as a candidate therapeutic agent for HCC cases that exhibit increased expression of FGF19.<i></i>.
|
29247039 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FGF19 is overexpressed in a significant proportion of human hepatocellular carcinomas (HCC), and activation of its receptor FGFR4 promotes HCC cell growth.
|
25346390 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interference with FGF19-FGFR4 signaling represents a novel strategy in HCC therapy.
|
28249259 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection.<i>See related commentary by Subbiah and Pal, p. 1646</i>.<i>This article is highlighted in the In This Issue feature, p. 1631</i>.
|
31575541 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data bona fide suggest the therapeutic potential of targeting the FXR-FGF19 axis to reduce hepatic BA synthesis in the control of BA-associated risk of fibrosis and hepatocarcinoma development.
|
30464200 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels.
|
28189755 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial.
|
30403487 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further investigation of FGF19/FGFR4 signaling is important for potential early diagnosis and therapeutic targeting in HCC patients.
|
29973237 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although it is widely assumed that CCND1 is the main driving oncogene of this common amplicon (15% frequency in HCC), both forward-transformation assays and RNAi-mediated inhibition in human HCC cells established that FGF19 is an equally important driver gene in HCC.
|
21397858 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
|
24798001 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
|
27384874 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we hypothesize that the FGF19-FGFR4 axis may affect the effectiveness of sorafenib in the treatment of HCC.
|
28983785 |
2018 |